Abivax Shares Rally After Phase 3 Maintenance Data for Ulcerative Colitis Therapy
Abivax SA ADR (NASDAQ:ABVX) shares rose sharply in after-hours trading following Phase 3 ABTECT Maintenance Part 2 data showing sustained clinical and endoscopic remission in patients treated with 50 mg obefazimod through Week 44. The results include remission rates for patients who failed induction or relapsed, dose-escalation rescue outcomes, and…